MNTA

Momenta Pharmaceuticals Inc

A biotechnology company that developed therapies for rare, immune-mediated diseases, Momenta Pharmaceuticals was born in 2001 from an MIT professor's lab studying complex sugars. Its name comes from the Latin plural of "momentum," reflecting its drive to speed up drug discovery. Its flagship drug, nipocalimab, targets the FcRn receptor to tame harmful antibodies in autoimmune conditions, and the company was acquired by Johnson & Johnson in 2020.

Recent Activity

Show $

2020Q3

2 sells

Maverick CapitalEXIT

-2.31M shares

Maverick CapitalEXIT

-2.31M shares

Viking Global InvestorsEXIT

-946.2K shares

Viking Global InvestorsEXIT

-946.2K shares

2020Q2

2 buys

Maverick CapitalADD

+143.7K shares(+6.6%)

Maverick CapitalADD

+143.7K shares(+6.6%)

Viking Global InvestorsNEW

+946.2K shares

Viking Global InvestorsNEW

+946.2K shares

2020Q1

1 buy

Maverick CapitalNEW

+2.17M shares

Maverick CapitalNEW

+2.17M shares